Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available: early-phase trial registry

Q: How many clinical trials are there for Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available?

PlainTrial tracks 1 US clinical trials for Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available, of which 0 are currently recruiting.

Q: Which interventions appear most often on Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available trial records?

MSC2156119J is the most-linked intervention name on Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available records (1 trial links). Names are sponsor-reported on ClinicalTrials.gov.

Q: How do I find a recruiting trial for Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Compiled by PlainTrial · August 8, 2026

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

Browse conditions → How counts are built

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available: 1 US clinical trial tracked, none currently recruiting.

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is EMD Serono, running 1 of these trials.

Enrollment posture brief

Registry condition patients-with-solid-tumors-either-refractory-to-standard-therapy-or-for-which-no

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Open-enrollment share among volume-matched conditions near Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available is recruiting below its size-band peers.

0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Indexed trials (enrollment closed)

1 total, page 1 of 1

COMPLETED Phase 1 149 participants

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

EMD Serono

NCT01014936

Phase Distribution

Phase	Trial count
Phase 1	1

Top Sponsors

EMD Serono 1 trials

Named interventions

Most-linked intervention names on Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

MSC2156119J Drug

1 trials

US sites by state

Facility locations filed on Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available trials. A trial with sites in several states counts in each.

Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

No Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
EMD Serono sponsors the most Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available trials on record, review their full trial history before evaluating a specific study. See EMD Serono's trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available condition card totals 1 registered trials; most-linked intervention MSC2156119J; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.